101111-25-5

Basic information

• Product Name: Methyl [4-(benzyloxy)-3-bromophenyl]acetate
• Synonyms: Benzeneacetic acid, 3-bromo-4-(phenylmethoxy)-, methyl ester
• CAS NO: 101111-25-5
• Molecular Formula: C16H15BrO3
• Molecular Weight: 335.197
• Mol File: 101111-25-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Methyl [4-(benzyloxy)-3-bromophenyl]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl [4-(benzyloxy)-3-bromophenyl]acetate(101111-25-5)
• EPA Substance Registry System: Methyl [4-(benzyloxy)-3-bromophenyl]acetate(101111-25-5)

Safety Data

• Hazardous Substances Data: 101111-25-5(Hazardous Substances Data)

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 100-39-0 benzyl bromide 

Downstream Products

• 6877-26-5 C₂₀H₂₃NO₄ 
• 30413-84-4 (-)-corydalmine 
• 1429118-97-7 14-(R)-3,10-dibenzyloxy-2,9-dimethoxytetrahydroprotoberberine 
• 1422431-61-5 14-(S)-3,10-dibenzyloxy-2,9-dimethoxytetrahydroprotoberberine 
• 1429118-96-6 C₂₇H₂₇NO₄ 
• 1429118-95-5 14-(R)-10-benzyloxy-2,3-methylenedioxy-9-methoxytetrahyrdooxyprotoberberine 
• 1422431-60-4 14-(S)-10-benzyloxy-2,3-methylenedioxy-9-methoxytetrahyrdooxyprotoberberine 
• 1422431-54-6 (R)-2,10-dibenzyloxy-3,9-dimethoxytetrahydroprotoberberine 
• 1196996-62-9 (S)-2,10-dibenzyloxy-3,9-dimethoxytetrahydroprotoberberine 
• 1429118-85-3 (S)-(3-(benzyloxy)-6-((6-(benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-2-methoxyphenyl)methanol 
• 1429118-83-1 (S)-(3-(benzyloxy)-2-methoxy-6-((5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)methyl)phenyl)methanol 
• 1196996-66-3 (3-(benzyloxy)-6-(((S)-7-(benzyloxy)-1,2,3,4-tetrahydro-6-methoxyisoquinolin-1-yl)-methyl)-2-methoxyphenyl)methanol 
• 1422431-50-2 (S)-3-(benzyloxy)-6-((6-(benzyloxy)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-2-methoxybenzyl acetate 
• 1422431-49-9 (S)-3-(benzyloxy)-2-methoxy-6-((5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)methyl)benzyl acetate 

Relevant articles and documents

Preparation method of isoquinoline alkaloid L-corydalmine

The invention belongs to the field of medical chemistry, and provides a preparation method of L-corydalmine or pharmaceutically acceptable salts thereof. The method comprises the following steps of: in the presence of an organic solvent, catalyzing by pal

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile

An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D1, D2 and serotonin 5-HT 1A and 5-HT2A receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D1 receptor with Ki values of 50 and 6.3 nM, while both compounds act as D2 receptor antagonists (Ki = 305 and 145 nM, respectively) and 5-HT1A receptor full agonists (Ki = 149 and 908 nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT1A receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.